RT Journal Article
SR Electronic
T1 Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.29.21264077
DO 10.1101/2021.09.29.21264077
A1 Ades, A E
A1 Gordon, Fabiana
A1 Scott, Karen
A1 Collins, Jeannie
A1 Thorne, Claire
A1 Pembrey, Lucy
A1 Chappell, Elizabeth
A1 Mariné-Barjoan, Eugènia
A1 Butler, Karina
A1 Indolfi, Giuseppe
A1 Gibb, Diana M
A1 Judd, Ali
YR 2021
UL http://medrxiv.org/content/early/2021/09/30/2021.09.29.21264077.abstract
AB Background Current guidelines recommend that infants born to women with hepatitis C (HCV) viremia are screened for HCV antibody at age 18 months, and if positive, referred for RNA testing at 3 years to confirm chronic infection. This policy is based in part on analyses suggesting 25%-40% of vertically acquired HCV infections clear spontaneously within 4-5 years.Methods Data on 179 infants with RNA and/or anti-HCV evidence of vertically acquired viraemia (single PCR+) or confirmed infection (2 PCR+ or anti-HCV beyond 18 months) in three prospective European cohorts were investigated. Ages at clearance of viremia and confirmed infection were estimated taking account of interval censoring and delayed entry. We also investigated clearance in infants in whom RNA was not detectable until after 6 weeks.Results Clearance rates decline rapidly over the first 6 months. An estimated 90.6% (95%CrI: 83.5-95.9) of viremia cleared by 5 years, most within 3 months, and 65.9% (50.1-81.6) of confirmed infection cleared by 5 years, at a median 12.4 (7.1-18.9) months. If treatment began at age 6 months, 18 months or 3 years, at least 59.0% (42.0-76.9), 39.7 (17.9-65.9), and 20.9 (4.6-44.8) of those treated would clear without treatment. In seven (6.6%) confirmed infections, RNA was not detectable until after 6 weeks, and in 2 (1.9%) not until after 6 months. However, all such cases subsequently cleared.Conclusions Most viraemia clears within 3 months, and most confirmed infection by 3 years. Delaying treatment avoids but does not eliminate over-treatment and should be balanced against loss to follow-up.Key points Based on a re-analysis of the largest purely prospective dataset assembled so far, 66% (50-82) of confirmed vertically acquired HCV clears spontaneously by age 5 years, rather than the 25-40% assumed in guidelines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Council [MR/R019746/1], through the Joint Global Health Trials scheme. Work at GOSICH was supported by the National Institute of Health Research Biomedical Research Centre, Great Ormond Street Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Health Sciences Research Ethics Committee at the University of BristolAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analysed for this paper was secondary. Individual patient data were requested from the studies listed in the manuscript and must be requested from the original research teams.